Cargando…
A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression
BACKGROUND: A novel anticancer drug 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (ECyd, TAS106) has been shown to radiosensitize tumor cells and to improve the therapeutic efficiency of X-irradiation. However, the effect of TAS106 on cellular DNA repair capacity has not been elucidated. Our aim i...
Autores principales: | Meike, Shunsuke, Yamamori, Tohru, Yasui, Hironobu, Eitaki, Masato, Matsuda, Akira, Morimatsu, Masami, Fukushima, Masakazu, Yamasaki, Yasundo, Inanami, Osamu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161955/ https://www.ncbi.nlm.nih.gov/pubmed/21798026 http://dx.doi.org/10.1186/1476-4598-10-92 |
Ejemplares similares
-
Antitumor Activity and Pharmacokinetics of TAS‐106, l‐(3‐C‐Ethynyl‐β‐D‐ribo‐pentofuranosyl)cytosine
por: Shimamoto, Yuji, et al.
Publicado: (2001) -
A Nucleoside Anticancer Drug, 1-(3-C-Ethynyl-β-D-Ribo-Pentofuranosyl)Cytosine, Induces Depth-Dependent Enhancement of Tumor Cell Death in Spread-Out Bragg Peak (SOBP) of Proton Beam
por: Maeda, Kenichiro, et al.
Publicado: (2016) -
Cellular and Biochemical Mechanisms of the Resistance of Human Cancer Cells to a New Anticancer Ribo‐nucleoside, TAS‐106
por: Shimamoto, Yuji, et al.
Publicado: (2002) -
Sensitivity of Human Cancer Cells to the New Anticancer Ribo‐nucleoside TAS–106 Is Correlated with Expression of Uridine‐cytidine Kinase 2
por: Shimamoto, Yuji, et al.
Publicado: (2002) -
Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells
por: Eitaki, Masato, et al.
Publicado: (2012)